| Eli Lilly researches gain access to tissue biomarker analysis tech | Posted on 27/03/2008 in Pharmaceutical Company Product News HistoRx has announced that it has signed a three-year agreement with Eli Lilly to provide the company's researchers with broad access to its Aqua technology for tissue biomarker analysis.
Under the terms of the agreement, researchers at Lilly will gain access to the technology for use in drug discovery, preclinical research and clinical development.
HistoRx will be able to commercialise the reagants and assays developed during the lifetime of the collaboration for use in predictive diagnostics.
This agreement extends and expands the scope of a previous agreement between the firms signed in 2005 that saw Lilly apply the HistoRx Aqua technology to selected pharmaceutical development programmes for advancement.
Rana K Gupta, chief executive officer of HistoRx, said: "We consider this expanded agreement with Lilly, one of the world's leading innovation-driven pharmaceutical companies, to be a tremendous validation of the HistoRx Aqua technology."
He added that the revealing of more reliable and stronger statistical correlations connecting the expression of protein biomarkers with predictions of patients' response to therapy and disease outcome will give drug research and development programmes at Lilly a significant boost.
In April 2007, Lilly presented over a dozen studies at the annual meeting for the American Association for Cancer Research, with the majority of these focused on the use of biomarkers and other pharmacogenomic information to enhance available treatment options.
Other news stories from 27/03/2008
Read more in the Zenopa News Archive
How this news is generated
|  |
|
